These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 1690479)

  • 21. Functional and anatomical effects of hormonally induced experimental prostate growth: a urodynamic model of benign prostatic hyperplasia (BPH) in the beagle.
    Yokota T; Honda K; Tsuruya Y; Nomiya M; Yamaguchi O; Gotanda K; Constantinou CE
    Prostate; 2004 Feb; 58(2):156-63. PubMed ID: 14716740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Drugs for the treatment of benign prostatic hypertrophy].
    Caprino L
    Minerva Urol Nefrol; 2000 Jun; 52(2):87-92. PubMed ID: 11085067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia.
    Lepor H; Knapp-Maloney G; Sunshine H
    J Urol; 1990 Dec; 144(6):1393-7; discussion 1397-8. PubMed ID: 1700152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Evaluation of the effectiveness of prazosin in conservative treatment of benign prostatic hypertrophy].
    Górecki R; Krzeski T; Wasik J; Borówka A
    Pol Tyg Lek; 1992 Jun 15-29; 47(24-26):549-51. PubMed ID: 1282713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The mechanism of action of the alpha-adrenoblocker prazosin on bladder function in patients with benign prostatic hyperplasia].
    Loran OB; Vishnevskiĭ AE
    Urol Nefrol (Mosk); 1997; (4):19-22. PubMed ID: 9381614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alpha blocker prazosin for the treatment of benign prostatic hypertrophy (BPH).
    Punekar SV; Kelkar AR; Gavande PM; Rao NR; Date JA; Prem AR
    J Postgrad Med; 1995; 41(4):99-101. PubMed ID: 10707729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical overview of prazosin in the treatment of prostatic obstruction.
    Milroy E
    Urol Int; 1990; 45 Suppl 1():1-3. PubMed ID: 1690474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Incidence of the form and caliber of urethral resistance. Evaluation for a normal masculine urethra and in cases of obstruction due to prostatic hypertrophy].
    Glémain P; Cordonnier JP; Bochereau G; Baron M; Le Normand L; Buzelin JM
    Prog Urol; 1993 Dec; 3(6):995-1015; discussion 1006-8. PubMed ID: 7508314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term effects of finasteride on invasive urodynamics and symptoms in the treatment of patients with bladder outflow obstruction due to benign prostatic hyperplasia.
    Tammela TL; Kontturi MJ
    J Urol; 1995 Oct; 154(4):1466-9. PubMed ID: 7544845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of an alpha 1-blocker, YM-12617, in micturition difficulty.
    Kawabe K; Niijima T
    Urol Int; 1987; 42(4):280-4. PubMed ID: 2445091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of prazosin in men with symptoms of bladder neck obstruction and a non-hyperplastic prostate.
    Hedlund H; Andersson KE
    Scand J Urol Nephrol; 1989; 23(4):251-4. PubMed ID: 2480639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prazosin in the treatment of prostatic obstruction. A placebo-controlled study.
    Kirby RS; Coppinger SW; Corcoran MO; Chapple CR; Flannigan M; Milroy EJ
    Br J Urol; 1987 Aug; 60(2):136-42. PubMed ID: 2444306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical effect of new alpha-adrenergic blocker on micturition disturbance of neurogenic bladder and lower urinary tract obstruction].
    Takimoto Y; Kitamura K; Fuse T; Kawazoe K; Hirano D; Amagai T; Kiyotaki S
    Hinyokika Kiyo; 1983 Feb; 29(2):255-63. PubMed ID: 6145342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urethral pressure profile and hemodynamic effects of phenoxybenzamine and prazosin in non-sedated male beagle dogs.
    Fischer JR; Lane IF; Cribb AE
    Can J Vet Res; 2003 Jan; 67(1):30-8. PubMed ID: 12528826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of prazosin and carbachol in patients with benign prostatic obstruction.
    Hedlund H; Andersson KE
    Scand J Urol Nephrol; 1988; 22(1):19-22. PubMed ID: 2455331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Botulinum toxin A injection to the bladder neck and urethra for medically refractory lower urinary tract symptoms in men without prostatic obstruction.
    Chen JL; Chen CY; Kuo HC
    J Formos Med Assoc; 2009 Dec; 108(12):950-6. PubMed ID: 20040460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of alpha blockers in the treatment of BPH: a critical review of clinical results.
    Von Heland M; Casale P
    Arch Esp Urol; 1994 Nov; 47(9):873-81; discussion 881-2. PubMed ID: 7530943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of KT-611 (Naftopidil) on the contraction of human prostatic tissue and its use in benign prostatic obstruction].
    Yamanaka N; Yamaguchi O; Kameoka H; Fukaya Y; Yokota T; Shiraiwa Y; Yokoyama J; Kumakawa K; Itou K; Kuma Y
    Hinyokika Kiyo; 1991 Dec; 37(12):1759-72. PubMed ID: 1723843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Therapeutic effect of Robaveron tablet (KN-7) on urinary disturbance by benign prostatic hypertrophy].
    Sonoda T; Endo H; Maru A; Sasaki K; Kuroda K; Takamura T; Inada F; Rokuzyo M; Ohori T; Kubo T
    Hinyokika Kiyo; 1985 Mar; 31(3):553-62. PubMed ID: 2411118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
    Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E
    Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.